What is the current stock price of MBX Biosciences, Inc. Common Stock (MBX)?

As of the latest market data, MBX Biosciences, Inc. Common Stock (MBX) is trading at $31.88. The stock has seen a gain of 0.41% today.

Does MBX Biosciences, Inc. Common Stock (MBX) pay a dividend?

Based on current data, MBX Biosciences, Inc. Common Stock does not have a confirmed active dividend policy.

What is the market cap of MBX Biosciences, Inc. Common Stock?

The current market capitalization of MBX Biosciences, Inc. Common Stock (MBX) is approximately unavailable.

MBX

MBX Biosciences, Inc. Common Stock·Healthcare

31.88

0.409%(+0.13)

Close Price

36.31

13.896%(+4.43)

Pre-Market

Last Updated: — ET

52W L: $9.4352W H: $45.85

MBX NEWS

fool.com

15h ago

Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run

MBX Biosciences, a clinical-stage biotech developing peptide therapies, reported a notable insider sale after a year of rapid stock gains.

globenewswire.com

1d ago

MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City

CARMEL, Ind. and BURLINGTON, Mass.

seekingalpha.com

May 14

Microbix Biosystems Inc. (MBX:CA) Q2 2026 Earnings Call Transcript

seekingalpha.com

May 11

MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics Portfolio Transcript

marketbeat.com

May 11

MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push

MBX Biosciences NASDAQ: MBX used its Obesity Day event to outline preliminary clinical data for its lead obesity candidate MBX 4291, introduce a new preclinical obesity program and reiterate key development milestones across its endocrine and metabolic disease pipeline.

globenewswire.com

May 11

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing

Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo)

Company Profile

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2000-01-14

Beta

0.78

Websitembxbio.com↗